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ABSTRACT
Combinations between an angiotensin con-
verting enzyme (ACE) inhibitor or an angio-
tensin II receptor blocker (ARB) and
hydrochlorothiazide (HCTZ) are among the
recommended treatments for hypertensive
patients uncontrolled by monotherapy. Four
randomized, double-blind, parallel group
studies with a similar design, including 1469
hypertensive patients uncontrolled by a previ-
ous monotherapy and with C1 cardiovascular
risk factor, compared the efficacy of a combi-
nation of a sulfhydryl ACE inhibitor (zofenopril
at 30 or 60 mg) or an ARB (irbesartan at 150 or
300 mg) plus HCTZ 12.5 mg. The extent of
blood pressure (BP)-lowering was assessed in the
office and over 24 h. Pleiotropic features of the
treatments were evaluated by studying their
effect on systemic inflammation, organ damage,
arterial stiffness, and metabolic biochemical
parameters. Both treatments similarly reduced
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office and ambulatory BPs after 18–24 weeks. In
the ZODIAC study a larger reduction in high
sensitivity C reactive protein (hs-CRP) was
observed under zofenopril (-0.52 vs. ?0.97 mg/
dL under irbesartan, p = 0.001), suggesting a
potential protective effect against the develop-
ment of atherosclerosis. In the ZENITH study
the rate of carotid plaque regression was signif-
icantly larger under zofenopril (32% vs. 16%;
p = 0.047). In the diabetic patients of the
ZAMES study, no adverse effects of treatments
on blood glucose and lipids as well as an
improvement of renal function were observed.
In patients with isolated systolic hypertension
of the ZEUS study, a slight and similar
improvement in renal function and small
reductions in pulse wave velocity (PWV), aug-
mentation index (AI), and central systolic BP
were documented with both treatments. Thus,
the fixed combination of zofenopril and HCTZ
may have a relevant place in the treatment of
high-risk or monotherapy-treated uncontrolled
hypertensive patients requiring a more prompt,
intensive, and sustained BP reduction, in line
with the recommendations of current
guidelines.
Keywords: Ambulatory blood pressure;
Angiotensin converting enzyme inhibitors;
Angiotensin II receptor blockers; Essential
hypertension; Hydrochlorothiazide; Irbesartan;
Office blood pressure; Thiazide diuretics;
Zofenopril
INTRODUCTION
Large intervention trials have shown that the
majority of hypertensive patients may need a
combination of two or more antihypertensive
medications to achieve satisfactory blood pres-
sure (BP) control and effective cardiovascular
(CV) protection [1, 2]. This holds true particu-
larly for patients at high risk for CV events, such
as older individuals, patients with diabetes or
the metabolic syndrome, co-existing CV dis-
ease, or other associated clinical conditions
[3, 4]. According to the evidence provided by
major intervention trials, current guidelines for
the management of arterial hypertension
acknowledge and recommend the use of com-
bination treatment, particularly when BP con-
trol with initial monotherapy is inadequate
[5–8].
Amongst the most effective two-drug anti-
hypertensive combinations are those between
an antagonist of the renin–angiotensin–aldos-
terone system (RAAS), such as an angiotensin
converting enzyme (ACE) inhibitor or an
angiotensin II receptor blocker (ARB), and a
thiazide diuretic. The mechanism of action of
such a combination implies a synergistic and
opposite effect on the RAAS, in which the ACE
inhibitor or the ARB antagonize the coun-
ter-regulatory system activity triggered by the
diuretic, thus improving the efficacy and toler-
ability of single drug components [9–11].
Recently, we published four randomized,
double-blind, parallel group, direct comparative
studies (also called ‘‘Z’’ studies, because of the
common initial of their acronyms: ZODIAC,
ZENITH, ZAMES, and ZEUS) which were plan-
ned to gain a deeper insight into the mecha-
nisms of the antihypertensive effects of a
two-drug fixed combination between a RAAS
antagonist and a thiazide diuretic [12–15]. In
these non-inferiority trials, efficacy and safety
of the sulfhydryl ACE inhibitor zofenopril and
of the ARB irbesartan both combined with
hydrochlorothiazide (HCTZ) 12.5 mg were tes-
ted in hypertensive patients with one or more
CV risk factors beyond hypertension (including
diabetes, metabolic syndrome, and advanced
age) and not responding to a previous
monotherapy. In all studies, zofenopril and
irbesartan were started at a dose of 30 and
150 mg, respectively, and were increased during
the course of the follow-up to 60 and 300 mg, in
non-responders, in order to check the effec-
tiveness and tolerability of a highest dose of the
drugs. Efficacy was evaluated not only in the
office but also over 24 h by ambulatory blood
pressure monitoring (ABPM). In addition,
ancillary or pleiotropic features of the study
drugs were evaluated by studying their effect on
inflammation, target organ damage, arterial
stiffness, and metabolic biochemical parameters
(blood glucose and lipids). A summary of the
study designs and an overview of the number of
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patients included in each individual study and
the main patient features are reported in
Table 1. In total, 1535 hypertensives were
recruited in 126 centers in six European coun-
tries (Italy, Greece, Lithuania, Romania, Turkey,
and Russia). Both drugs had a similar efficacy on
office and ambulatory BP but some differences
between the study medications could be
observed for secondary efficacy endpoints. In
the ZODIAC study, treatment with the zofeno-
pril combination was associated with a larger
(p = 0.001) reduction of hs-CRP (-0.52 mg/dL)
than irbesartan (?0.97 mg/dL, p = 0.001), sug-
gesting a potential protective effect against
vascular inflammation, a well-known promoter
of atherosclerosis at all its stages, from the
endothelial cell dysfunction to the culmination
in acute coronary syndrome [16, 17]. In the
ZENITH study, both treatments had a similar
positive effect on regression of cardiac and renal
damage, whereas a larger proportion of patients
showing carotid plaque regression was observed
under zofenopril (31.6% vs. 16.1%; p = 0.047),
particularly in the subgroup of patients taking
the low dose of zofenopril (30 mg) plus HCTZ
12.5 mg (4.7% vs 10.0% irbesartan 150 mg plus
HCTZ 12.5 mg; p = 0.043). These findings fur-
ther confirmed the potent antiatherosclerotic
effects of RAAS blockade and in particular of
zofenopril, which are mediated by its antihy-
pertensive, anti-inflammatory, antiproliferative,
and oxidative stress-lowering properties
[18, 19]. In the ZAMES study, metabolic
parameters and renal function were not altered
by treatments, except for albumin-to-creatinine
ratio (ACR), whose reduction with treatment
was larger under irbesartan combined with the
thiazide diuretics (-24.2 vs. -9.9 mg/g with
zofenopril; p = 0.027). The metabolic neutrality
of treatment documented in this large study is
an important finding, given the relevant notion
that thiazide diuretics may induce metabolic
abnormalities and that patients with metabolic
syndrome may be particularly susceptible to
such effects [20]. Finally, in a subgroup of 93
elderly hypertensive patients of the ZEUS study,
treatment with zofenopril or irbesartan was
associated with small reductions in central SBP
and arterial stiffness indices (pulse wave veloc-
ity or PWV and augmentation index or AI),
which were similar between the two study drugs
at any time point of the study, including the
first 6 weeks when all patients were treated with
the lowest dose of zofenopril or irbesartan
combined with the thiazide diuretic. Though
such improvements were not striking as a result
of the limited vascular impairments of the
patients, they are relevant, because arterial
stiffness represents a late manifestation of
increase elastic arterial stiffness [21], and
because they are consistent with those observed
in previous randomized studies with the same
classes of antihypertensive agents [22–24].
Given these premises, in the next sections of
this review we will briefly summarize and dis-
cuss other results of the ‘‘Z’’ studies, which were
not presented in the original publications.
These include outcomes based on low dose
treatment of both study medications, pooled
individual analysis of ABPM data and of safety
data. This article is based on previously con-
ducted studies and does not involve any new
studies of human or animal subjects performed
by any of the authors.
EFFICACY IN LOW DOSE
SUBGROUP
As expected on the basis of the study design and
objectives, most of the patients enrolled in the
‘‘Z’’ studies took the high dose of zofenopril
(75%) and the high dose of irbesartan (69%).
In three of the four ‘‘Z’’ studies, the efficacy
of low dose zofenopril combination (30 mg)
and low dose irbesartan combination (150 mg)
was also assessed: this subanalysis was com-
pelling because the zofenopril 30 mg plus HCTZ
12.5 mg combination is at present the only
marketed fixed-drug combination of zofenopril
with a thiazide diuretic. Average office BP
changes with treatment under the low drug
doses in these studies are shown in Fig. 1. No
patients were under low dose drug treatment at
study end in the ZAMES study because only
patients forcedly up-titrated to the high dose
were kept in that study.
In the ZODIAC study at the end of the
18 weeks, office sitting DBP reductions were
significantly larger (p = 0.022) with zofenopril
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30 mg plus HCTZ [n = 55; 19.8 (22.8, 16.8)
mmHg] than with irbesartan 150 mg plus HCTZ
[n = 69; 14.5 (17.9, 11.1) mmHg], whereas they
were similar for SBP [zofenopril: 25.8 (30.5,
21.2) mmHg vs. irbesartan: 22.0 (27.1, 16.8)
mmHg; p = 0.274] [25]. In the patients of the
ZENITH study taking the low drug doses at
study end (n = 223), the proportion of respon-
ders did not differ (p = 0.693) between zofeno-
pril (76.4%) and irbesartan (78.9%), as well as
the office SBP and DBP reductions (Fig. 1) [13].
Also in the subgroup of patients with moder-
ate–severe hypertension (office BP C160 mmHg
and DBP C100 mmHg) taking the lowest dose
during the study, the zofenopril combination
was associated with an antihypertensive
response similar to that of the irbesartan com-
bination (88.9% vs. 80.0%; p = 0.596).
In the patients of the ZEUS study maintain-
ing the low drug doses throughout the study
(n = 77), the magnitude of the daytime BP
lowering was always slightly larger under
zofenopril 30 mg plus HCTZ 12.5 mg than
under irbesartan 150 mg plus HCTZ 12.5 mg
[14]. In this study subgroup, a statistically
significant (p = 0.028) difference in favor of
zofenopril-treated patients was achieved at
study end [16.2 (20.0, 12.5) mmHg vs. 11.2
(14.4, 7.9) mmHg irbesartan-treated patients].
For the low dose subgroup also the percentage
of patients showing daytime SBP normalization
(\135 mmHg) and daytime SBP response (SBP
\135 mmHg or reduction C10 mmHg) at study
end was significantly larger under zofenopril
(88.9% and 91.7%) than under irbesartan
(73.2% and 78.0%; p = 0.017 and p = 0.024,
respectively).
The high rate of BP control and the good
BP-lowering effect observed in the ‘‘Z’’ studies
with both RAAS antagonists at the lowest dosage
confirm recommendations of current guidelines
which indicate a two-drug lowdose combination
of an ACE inhibitor or an ARB and a thiazide
diuretic as a reasonable alternative to high dose
monotherapy in patients previously classified as
non-responders to monotherapy [6, 7]. It also
strengthens the evidence from previous large
randomized studies in patients with mild–mod-
erate hypertension, in which treatment with the




















































































Fig. 1 Mean changes (D) with treatment (and 95%
confidence interval) in office systolic blood pressure
(SBP) and diastolic blood pressure (DBP) in the ZODIAC
(a) and ZENITH study (b), and mean daytime SBP
changes in the ZEUS study (c), in the subgroup of patients
receiving the low drug doses during the study. The p values
refer to the statistical significance of the between-treatment
difference
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HCTZ 12.5 mg once-daily showed a greater effi-
cacy than the monotherapy with either agent,
with an increase in the response rate up to
55–65% [26, 27].
EFFICACY OVER 24H
As detailed in the publications of the individual
‘‘Z’’ studies, the good office BP control obtained
with zofenopril and irbesartan was confirmed
over 24 h by ABPM, which was available for
53% of patients included in primary endpoint
analysis. In order to better assess the antihy-
pertensive effect of the drugs over 24 h, we
pooled individual ABPM data of the ZODIAC,
ZENITH, and ZAMES studies, namely the ‘‘Z’’
studies with similar inclusion criteria (the ZEUS
study included only isolated systolic hyperten-
sion or ISH patients, and selection of patients
for study entry was based not only on office but
also on ambulatory BP). In the 561 patients of
the pooled ABPM data analysis, the 24-h anti-
hypertensive effect was similar between the two
drugs, regardless of the dose employed: 24-h
SBP was reduced by 7.6 (9.5, 5.7) mmHg under
zofenopril and by 9.5 (11.2, 7.7) mmHg under
irbesartan (p = 0.155), whereas DBP dropped by
5.5 (6.6, 4.4) mmHg and by 6.6 (7.6, 5.5) mmHg
(p = 0.170).
As shown in Fig. 2a, both drugs displayed a
similarly smooth and long-lasting antihyper-
tensive effect, with similar smoothness indices
for SBP [zofenopril: 0.57 (0.41, 0.73) vs. irbe-
sartan: 0.76 (0.61, 0.91); p = 0.100] and DBP
[0.50 (0.36, 0.63) vs. 0.61 (0.49, 0.74);
p = 0.217]. Interestingly, the magnitude of the
24-h BP reduction yielded by zofenopril and
irbesartan in the ‘‘Z’’ studies was comparable
with that observed in previous studies based on
ABPM and making use of the same doses of the
two drug combinations [28, 29].
The BP-lowering effect of the two tested
drugs was also similar in the low (n = 157, 28%
of patients) and the high drug dose (n = 404;
72%) subgroup, either over 24 h or in the last
6 h from the last drug intake: in this subperiod
the BP reduction was still comparable between
zofenopril and irbesartan and corresponded to
75–85% of the overall 24-h effect (Fig. 3).
In the low drug dose subgroup BP was
effectively reduced both under zofenopril
(30 mg) and irbesartan (150 mg) plus HCTZ
12.5 mg for each hour of the 24 h (Fig. 2b).
Twenty-four hour BP was also similarly reduced
in subgroups of high risk patients such as males,
aged persons (C55 years for males and C65 years
for females), smokers and alcohol drinkers,
patients with diabetes or impaired fasting glu-
cose, patients with a high or very high cardio-
vascular risk, and patients with sustained
hypertension (namely those simultaneously




In the ZODIAC and ZENITH studies long-term
follow-up of patients treated with high dose
combination at study end was planned in order
to collect more information on study drug effi-
cacy and safety. Both drugs ensured a consistent
efficacy, together with a good tolerability (see
next section), also in the long-term follow-up
observation.
In the ZODIAC study at the end of the
18 weeks of double-blind treatment, 229 patients
among those receiving high dose combination
treatment entered anopen-label extensionphase
andwere followed up for an additional 14 weeks.
As shown in the upper panel of Fig. 4, both SBP
andDBP reductionswerewellmaintained during
long-term treatment and did not differ between
the two study arms.
In the 223 patients of the ZENITH study
receiving drug dose up-titration at the end of
the 18 weeks of treatment and continuing the
double-blind treatment for additional 30 weeks,
no difference was observed in office BP response
between the two treatment groups (28.6%
zofenopril vs. 22.1% irbesartan; p = 0.178) [13].
As shown in Fig. 4, in these patients, office and
24-h BPs were similarly reduced under zofeno-
pril and irbesartan combinations either at the
end of the 18 weeks or at the end of the exten-
sion phase. Likewise, the impact of treatment
on organ damage did not significantly differ
between the two study drugs.
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TOLERABILITY OF BOTH DRUG
COMBINATIONS
The overall tolerability profile of zofenopril and
irbesartan in the ‘‘Z’’ studies was good and
comparable with that in previous reports
[26, 30]. The safety population consisted of
1535 patients, of which 762 received the
zofenopril and 773 the irbesartan combination
(Table 3). Both drugs were well tolerated, with a
very limited number of adverse events, which
were well balanced between the two study arms
Fig. 2 Average hourly systolic blood pressure (SBP) and
diastolic blood pressure (DBP) values at baseline (B, dashed
line) and at the end of the double-blind treatment (T,
continuous line) in patients treated with zofenopril
30–60 mg plus hydrochlorothiazide (HCTZ) 12.5 mg or
irbesartan 150–300 mg plus hydrochlorothiazide 12.5 mg
in the whole 561 patients of the ZODIAC, ZENITH, and
ZAMES studies (a) and in those treated with the lowest
dose of zofenopril (30 mg) or irbesartan (150 mg) (b) and
with a valid ambulatory blood pressure monitoring
(ABPM)
Adv Ther (2017) 34:784–798 791
(25.2% of patients receiving zofenopril and
21.9% receiving irbesartan; p = 0.715). The
percentage of drug-related adverse events was
much smaller than that of overall adverse
events and still homogeneously distributed
between the two groups (9.4% zofenopril vs.
6.2% irbesartan; p = 0.273). In total, only 66
patients (4.3%) were withdrawn from the stud-
ies because of an adverse event, 38 in the
zofenopril (4.9%) and 28 in the irbesartan
treatment group (3.6%; p = 0.593). The most
common drug-related adverse event observed
under zofenopril was cough (1.8% of patients),
whereas dizziness was the most prevalent drug
adverse reaction in irbesartan-treated patients
(1.4%). All these side effects could be expected
with these classes of drugs. Interestingly, the
prevalence of cough with zofenopril in the ‘‘Z’’
studies (1.8%) was very close to that observed in
previous double-blind or open-label post-mar-
keting studies including 5794 hypertensive
patients (2.4%) [31]. The relatively low inci-
dence of cough in patients receiving zofenopril
might be related to its limited ACE inhibitor
potency at the lung level, responsible for a lesser
accumulation of bradykinin and a reduced
synthesis of prostaglandins in this tissue, as
found in some experimental and animal studies
[31].
In the ZODIAC and ZENITH studies safety
was also evaluated during a long-term follow-up
under high drug dose. In the ZODIAC study,
6.3% of zofenopril-treated patients and 1.9% of
irbesartan-treated patients reported a drug-re-
lated adverse event (p = 0.172) during the pro-
longed follow-up. No patients treated with
irbesartan were withdrawn from the study dur-
ing the extension phase, whereas five patients
(4.5%) dropped out in the zofenopril group
(p = 0.060). In the extension phase of the
ZENITH study, 12.3% of patients under high
dose zofenopril plus HCTZ and 11.4% under
high dose irbesartan plus HCTZ reported an
adverse event (p = 0.843). Treatment-related
adverse events occurred in 3.8% and 3.5%
of patients under the two study drugs
(p = 0.859); of these patients four were defi-
nitely withdrawn from the extension phase
(three taking zofenopril vs. one taking irbesar-
tan; p = 0.368) [13].
LIMITATIONS OF THIS REVIEW
A major limitation of this review is that it
reports mixed information from previous orig-
inal publications and from new pooled data or
subgroup analyses, particularly those based on






































































Fig. 3 24-h and last 6-h average systolic (SBP) and
diastolic blood pressure (DBP) reductions (D) with
treatment (and 95% confidence interval) in the 561
patients of the ZODIAC, ZENITH, and ZAMES studies
with a valid ambulatory blood pressure monitoring
(ABPM). Data are shown for the two subgroups receiving
low or high dose treatment at study end
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ABPM data. For this reason, it may be argued
that it cannot be classified either as a review or
an original paper. Indeed, in our review we
briefly summarized the main results of the
single studies, which helped introduce the
reader to the secondary results which were
available at the time of the original publica-
tions, but which were only outlined or even
omitted for reasons of space. The current
review gave us the possibility to add this
information in order to provide a comprehen-
sive presentation of all the available data of the
‘‘Z’’ studies. We think that this review may help
complete the large amount of information
deriving from the ‘‘Z’’ studies, which stand
amongst the largest double-blind randomized
studies comparing the effect of an ACE inhi-
bitor and an ARB in hypertensive patients with
multiple risk factors not controlled by a pre-
vious monotherapy.
CONCLUSIONS
In all the ‘‘Z’’ studies the combination between
zofenopril and HCTZ was always similarly
effective as that of irbesartan plus HCTZ, and it
performed well either at the lowest dose
(30 mg), which is the currently marketed one,
or at the highest (60 mg) dose. Zofenopril also
showed some ancillary features which suggest
that the fixed combination of this drug with
HCTZ may have a particular place in the treat-
ment of high-risk or monotherapy-treated
uncontrolled hypertensive patients requiring a
more prompt, intensive, and sustained BP
reduction, in line with the recommendations of
current guidelines [6, 7]. The effective BP
reduction and the large proportion of respon-
ders in both treatment arms in the ‘‘Z’’ studies
also support the findings of previous studies
that, in most patients not responding to a single
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Fig. 4 Average office systolic (SBP) and diastolic blood
pressure (DBP) (±SD) in the whole 32 weeks of the
ZODIAC study, for patients treated with high dose
zofenopril or irbesartan combination (a). Office and 24-h
SBP and DBP reductions (D) in the 48 weeks of treatment
(and 95% confidence interval) in the high dose subgroup
of the ZENITH study are reported in b
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antihypertensive medication, combination
treatment with two drugs may substantially
increase the chance of response [32, 33]. Vas-
cular protection afforded by the sulfhydryl ACE
inhibitor zofenopril may be related to its direct
antiatherogenic effects [19, 34, 35], both
reduction of systemic oxidative stress
[17, 19, 34–38] and nitric oxide deficiency
[17, 19, 38, 39], and enhancement of circulating
endothelial progenitor cells [36] together with
improved vascular function [40, 41].
In conclusion, results of the large ‘‘Z’’ studies
confirm that combination treatment between a
drug acting on the RAAS and a thiazide diuretic
should be among the preferred choices when
monotherapies fail to lower BP to or below tar-
get levels, particularly in patients displaying
multiple CV risk factors.
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39. Garcı́a-Estañ J, Ortiz MC, O’Valle F, et al. Effects of
angiotensin-converting-enzyme inhibitors in com-
bination with diuretics on blood pressure and renal
injury in nitric oxide-deficiency-induced hyperten-
sion in rats. Clin Sci (Lond). 2006;110:227–33.
40. Elijovich F, Laffer CL, Schiffrin EL. The effects of
atenolol and zofenopril on plasma atrial natriuretic
peptide are due to their interactions with target
organ damage of essential hypertensive patients.
J Hum Hypertens. 1997;11:313–9.
41. Pasini AF, Garbin U, Nava MC, et al. Effect of sulf-
hydryl and non-sulfhydryl angiotensin-converting
enzyme inhibitors on endothelial function in
essential hypertensive patients. Am J Hypertens.
2007;20:443–50.
798 Adv Ther (2017) 34:784–798
